New immune therapy aims to train body to attack rectal cancer cells

This early phase trial tests a biological product mix designed to train the immune system to recognize and kill CEA-positive rectal cancer cells. The study involves 20 participants with early-stage rectal cancer (Stage 0 to IIA) who have not yet developed symptoms or metastasis. The goal is to see if the treatment can activate the body's antigen-presenting cells to destroy cancer cells.